ABSTRACT
Serous endometrial intraepithelial carcinoma (SEIC) is a rare but highly aggressive form of uterine endometrial cancer. We report two cases of post-menopausal, 58-year-old patients with abundant vaginal bleeding and pelvic pain. The first patient had a history of surgical hysteroscopy in 2019 for an endocervical polyp. The second patient had a history of breast resection, axillary lymph node dissection, chemotherapy, radiation therapy, and tamoxifen therapy for breast carcinoma 6 years ago. An abdominal hysterectomy was performed in both patients. The pathological assessment showed serous endometrial intraepithelial carcinoma. Diagnosis of a serous proliferation of the uterus implies the exploration of other genital tract organs as well as distant locations in search of metastatic disease.
Subject(s)
Carcinoma in Situ , Cystadenocarcinoma, Serous , Endometrial Neoplasms , Uterine Neoplasms , Female , Humans , Middle Aged , Uterine Neoplasms/diagnosis , Endometrial Neoplasms/diagnosis , Endometrial Neoplasms/therapy , Cystadenocarcinoma, Serous/diagnosis , Cystadenocarcinoma, Serous/therapy , Cystadenocarcinoma, Serous/etiology , Uterus/pathology , Carcinoma in Situ/diagnosis , Carcinoma in Situ/therapyABSTRACT
OPINION STATEMENT: Despite the dismal prognosis of uterine serous carcinoma (USC), recent advances in molecular classification and targeted treatments have demonstrated improvements in survival outcomes for patients both in the upfront and recurrent treatment settings. After appropriate surgical staging and surgical cytoreduction as indicated, correct pathologic and molecular classification of USC is important to provide the most appropriate systemic adjuvant treatment. HER2-targeted agents are one of the most important advances in the treatment of USC in decades. Thus, for HER2-positive tumors, the addition of trastuzumab to conventional chemotherapy is indicated in those with advanced stage and/or recurrent disease. Treatment with pembrolizumab and lenvatinib suggests a 50% response rate in women with recurrent disease which serves as a promising targeted treatment strategy. Overall, emerging targeted therapeutic options with antibody-drug conjugates (i.e. targeting HER2, folic acid receptor alpha, or Trop-2), combinations of immunotherapies and tyrosine kinase inhibitors, PARP inhibitors, WEE1 inhibitors, and AKT inhibitors shed further promise in advancements of effective disease-modifying treatments for this unmet medical need for patients with USC. Several trials evaluating these targeted agents are ongoing, and those results are eagerly awaited. As such, enrollment of patients in clinical trials is highly recommended as it will provide patients with a higher level of personalized cancer care.
Subject(s)
Antineoplastic Agents , Cystadenocarcinoma, Serous , Immunoconjugates , Uterine Neoplasms , Humans , Female , Trastuzumab , Antineoplastic Agents/therapeutic use , Antineoplastic Agents/pharmacology , Uterine Neoplasms/diagnosis , Uterine Neoplasms/drug therapy , Cystadenocarcinoma, Serous/drug therapy , Cystadenocarcinoma, Serous/etiology , Immunoconjugates/therapeutic useABSTRACT
High-grade serous ovarian carcinoma (HGSOC) is the most aggressive type of ovarian cancer, often diagnosed at advanced stages. Molecularly, HGSOC shows high degree of genomic instability associated with large number of genetic alterations. BRD4 is the 4th most amplified gene in HGSOC, which correlates with poor patients' prognosis. BRD4 is constitutively expressed and generates two proteins, BRD4 long (BRD4-L) and BRD4 short (BRD4-S). Both isoforms contain bromodomains that bind to lysine-acetylated histones. Amongst other functions, BRD4 participates in chromatin organization, acetylation of histones, transcriptional control and DNA damage repair. In cancer patients with amplified BRD4, the increased activity of BRD4 is associated with higher expression of oncogenes, such as MYC, NOTCH3 and NRG1. BRD4-driven oncogenes promote increased tumor cells proliferation, genetic instability, epithelial-mesenchymal transition, metastasis and chemoresistance. Ablation of BRD4 activity can be successfully achieved with bromodomain inhibitors (BETi) and degraders, and it has been applied in pre-clinical and clinical settings. Inhibition of BRD4 function has an effective anti-cancer effect, reducing tumor growth whether ablated by single agents or in combination with other drugs. When combined with standard chemotherapy, BETi are capable of sensitizing highly resistant ovarian cancer cell lines to platinum drugs. Despite the evidence that BRD4 amplification in ovarian cancer contributes to poor patient prognosis, little is known about the specific mechanisms by which BRD4 drives tumor progression. In addition, newly emerging data revealed that BRD4 isoforms exhibit contradicting functions in cancer. Therefore, it is paramount to expand studies elucidating distinct roles of BRD4-L and BRD4-S in HGSOC, which has important implications on development of therapeutic approaches targeting BRD4.
Subject(s)
Cell Cycle Proteins/metabolism , Cell Transformation, Neoplastic/metabolism , Cystadenocarcinoma, Serous/etiology , Cystadenocarcinoma, Serous/metabolism , Disease Susceptibility , Ovarian Neoplasms/etiology , Ovarian Neoplasms/metabolism , Transcription Factors/metabolism , Animals , Biomarkers, Tumor , Cell Cycle Proteins/antagonists & inhibitors , Cell Cycle Proteins/chemistry , Cell Cycle Proteins/genetics , Cell Transformation, Neoplastic/genetics , Cystadenocarcinoma, Serous/pathology , Drug Resistance, Neoplasm/genetics , Female , Gene Expression Regulation, Neoplastic , Genomic Instability , Humans , Molecular Targeted Therapy , Nerve Tissue Proteins/metabolism , Ovarian Neoplasms/pathology , Ovarian Neoplasms/therapy , Protein Isoforms , Receptors, Cell Surface/metabolism , Structure-Activity Relationship , Transcription Factors/antagonists & inhibitors , Transcription Factors/chemistry , Transcription Factors/geneticsABSTRACT
Ovarian high-grade serous carcinomas (HGSCs) are a heterogeneous group of diseases. They include fallopian-tube-epithelium (FTE)-derived and ovarian-surface-epithelium (OSE)-derived tumors. The risk/protective factors suggest that the etiology of HGSCs is multifactorial. Inflammation caused by ovulation and retrograde bleeding may play a major role. HGSCs are among the most genetically altered cancers, and TP53 mutations are ubiquitous. Key driving events other than TP53 mutations include homologous recombination (HR) deficiency, such as BRCA 1/2 dysfunction, and activation of the CCNE1 pathway. HR deficiency and the CCNE1 amplification appear to be mutually exclusive. Intratumor heterogeneity resulting from genomic instability can be observed at the early stage of tumorigenesis. In this review, I discuss current carcinogenic hypotheses, sites of origin, etiologic factors, and molecular alterations of HGSCs.
Subject(s)
Carcinogenesis/pathology , Cystadenocarcinoma, Serous/pathology , Fallopian Tube Neoplasms/pathology , Ovarian Neoplasms/pathology , Animals , Cystadenocarcinoma, Serous/etiology , Fallopian Tube Neoplasms/etiology , Female , Humans , Neoplasm Grading , Ovarian Neoplasms/etiology , Risk FactorsABSTRACT
Nearly a third of patients with high-grade serous ovarian cancer (HGSC) do not respond to initial therapy and have an overall poor prognosis. However, there are no validated tools that accurately predict which patients will not respond. Our objective is to create and validate accurate models of prediction for treatment response in HGSC. This is a retrospective case-control study that integrates comprehensive clinical and genomic data from 88 patients with HGSC from a single institution. Responders were those patients with a progression-free survival of at least 6 months after treatment. Only patients with complete clinical information and frozen specimen at surgery were included. Gene, miRNA, exon, and long non-coding RNA (lncRNA) expression, gene copy number, genomic variation, and fusion-gene determination were extracted from RNA-sequencing data. DNA methylation analysis was performed. Initial selection of informative variables was performed with univariate ANOVA with cross-validation. Significant variables (p < 0.05) were included in multivariate lasso regression prediction models. Initial models included only one variable. Variables were then combined to create complex models. Model performance was measured with area under the curve (AUC). Validation of all models was performed using TCGA HGSC database. By integrating clinical and genomic variables, we achieved prediction performances of over 95% in AUC. Most performances in the validation set did not differ from the training set. Models with DNA methylation or lncRNA underperformed in the validation set. Integrating comprehensive clinical and genomic data from patients with HGSC results in accurate and robust prediction models of treatment response.
Subject(s)
Biomarkers, Tumor , Cystadenocarcinoma, Serous/diagnosis , Disease Susceptibility , Models, Biological , Ovarian Neoplasms/diagnosis , Adult , Aged , Aged, 80 and over , Case-Control Studies , Combined Modality Therapy , Computational Biology/methods , Cystadenocarcinoma, Serous/etiology , Cystadenocarcinoma, Serous/mortality , Cystadenocarcinoma, Serous/therapy , DNA Methylation , Disease Management , Female , Gene Expression Profiling , Gene Expression Regulation, Neoplastic , Genomics/methods , Humans , Middle Aged , Neoplasm Grading , Neoplasm Staging , Neoplasm, Residual/diagnosis , Ovarian Neoplasms/etiology , Ovarian Neoplasms/mortality , Ovarian Neoplasms/therapy , Prognosis , Reproducibility of Results , Retrospective Studies , Treatment OutcomeABSTRACT
(1) Background: Biomarkers might play a significant role in predicting the clinical outcomes of patients with ovarian cancer. By analyzing lipid metabolism genes, future perspectives may be uncovered; (2) Methods: RNA-seq data for serous ovarian cancer were downloaded from The Cancer Genome Atlas and Gene Expression Omnibus databases. The non-negative matrix factorization package in programming language R was used to classify molecular subtypes of lipid metabolism genes and the limma package in R was performed for functional enrichment analysis. Through lasso regression, we constructed a multi-gene prognosis model; (3) Results: Two molecular subtypes were obtained and an 11-gene signature was constructed (PI3, RGS, ADORA3, CH25H, CCDC80, PTGER3, MATK, KLRB1, CCL19, CXCL9 and CXCL10). Our prognostic model shows a good independent prognostic ability in ovarian cancer. In a nomogram, the predictive efficiency was notably superior to that of traditional clinical features. Related to known models in ovarian cancer with a comparable amount of genes, ours has the highest concordance index; (4) Conclusions: We propose an 11-gene signature prognosis prediction model based on lipid metabolism genes in serous ovarian cancer.
Subject(s)
Biomarkers, Tumor , Cystadenocarcinoma, Serous/etiology , Cystadenocarcinoma, Serous/metabolism , Lipid Metabolism , Ovarian Neoplasms/etiology , Ovarian Neoplasms/metabolism , Computational Biology , Cystadenocarcinoma, Serous/mortality , Cystadenocarcinoma, Serous/pathology , Databases, Genetic , Disease Susceptibility , Female , Gene Expression Profiling , Gene Expression Regulation, Neoplastic , Gene Regulatory Networks , Humans , Kaplan-Meier Estimate , Ovarian Neoplasms/mortality , Ovarian Neoplasms/pathology , Prognosis , ROC Curve , TranscriptomeABSTRACT
Aim: To explore FBXW7 protein-coding transcript isoform (α, ß and γ) expression, their functions and prognostic value in ovarian serous cystadenocarcinoma (OSC). Materials & methods: FBXW7 transcript data were collected from The Cancer Genome Atlas and the Genotype-Tissue Expression project. IOSE, A2780 and SKOV3 cells were used for in vitro and in vivo studies. Results: FBXW7α and FBXW7γ are dominant protein-coding transcripts that were downregulated in OSC. FBXW7γ overexpression reduced the protein expression of c-Myc, Notch1 and Yap1 and suppressed OSC cell growth in vitro and in vivo. FBXW7γ expression was an independent indicator of longer disease-specific survival (HR: 0.588; 95% CI: 0.449-0.770) and progression-free survival (HR: 0.708; 95% CI: 0.562-0.892). Conclusion: FBXW7γ is a tumor-suppressive and might be the only prognosis-related FBXW7 transcript in OSC.
Subject(s)
Alternative Splicing , Biomarkers, Tumor , Cystadenocarcinoma, Serous/etiology , Cystadenocarcinoma, Serous/mortality , F-Box-WD Repeat-Containing Protein 7/genetics , Gene Expression Regulation, Neoplastic , Ovarian Neoplasms/etiology , Animals , Cell Line, Tumor , Cystadenocarcinoma, Serous/metabolism , Cystadenocarcinoma, Serous/pathology , Disease Models, Animal , Fallopian Tubes/metabolism , Female , Humans , Kaplan-Meier Estimate , Mice , Neoplasm Metastasis , Neoplasm Staging , Ovarian Neoplasms/metabolism , Ovarian Neoplasms/pathology , Prognosis , RNA Isoforms , RNA, Messenger/genetics , Xenograft Model Antitumor AssaysABSTRACT
Aim: To uncover the molecular mechanisms of early-onset ovarian serous cystadenocarcinoma (EOOSC; patients <50 years old) and late-onset ovarian serous cystadenocarcinoma (LOOSC; patients ≥50 years old). Materials & methods: Bioinformatics was utilized to identify the key factors. Results: 478 EOOSC and 899 LOOSC individual differentially expressed genes were identified and enriched in different pathways. The expression of key genes LAG3, LRRC63 and MT1B significantly influenced the overall survival of EOOSC patients. The expression of key genes RDH12, NTSR1, ZSCAN16, CT45A3 and EPPIN_WFDC6 significantly affected the overall survival of LOOSC patients. Conclusions: The molecular mechanisms of EOOSC and LOOSC appear to be different, so that patients might be treated individually in respect of age.
Subject(s)
Cystadenocarcinoma, Serous/etiology , Ovarian Neoplasms/etiology , Adult , Aged , Aged, 80 and over , Computational Biology , Cystadenocarcinoma, Serous/genetics , Cystadenocarcinoma, Serous/mortality , Female , Humans , Middle Aged , Ovarian Neoplasms/genetics , Ovarian Neoplasms/mortalityABSTRACT
RATIONALE: Breast metastasis from serous borderline tumor with micro-invasive carcinoma of ovary is a very rare condition. The breast lump as the only clinical presentation is rarely seen in ovarian carcinoma, which may lead to be misdiagnosed, and the mechanism of breast metastasis from ovarian tumors in early stage still needs to be explored. Differentiation from primary breast cancer and extramammary malignancy is crucial because the treatment and prognosis are significantly different. PATIENT CONCERNS: A 33-year-old female presented with a painless, movable, 1.0â×â1.0âcm lump in the upper outer quadrant of the right breast for a month. DIAGNOSES: Breast metastasis of serous borderline tumor with micro-invasive ovarian carcinoma confirmed by pathology and immunohistochemistry. INTERVENTIONS: The patient underwent lumpectomy, bilateral ovarian tumor stripping operation and prophylactic chemotherapy. OUTCOMES: No signs of recurrence have been detected in 1.5 years of follow-up. LESSONS: Distant metastasis may occur in early stage of ovarian carcinoma. It is important to determine the origin of the primary tumor and develop an effective treatment strategy for patients. Imaging findings and pathological diagnostic criteria are important to accurately differentiate between metastasis and primary breast lesions, which may improve the patient's outcomes.
Subject(s)
Breast Neoplasms/diagnosis , Neoplasm Metastasis/diagnosis , Ovarian Neoplasms/complications , Adult , Breast Neoplasms/etiology , Breast Neoplasms/physiopathology , Cystadenocarcinoma, Serous/diagnosis , Cystadenocarcinoma, Serous/etiology , Cystadenocarcinoma, Serous/pathology , Female , Humans , Neoplasm Metastasis/pathology , Ovarian Neoplasms/physiopathology , Ultrasonography/methodsABSTRACT
PURPOSE: Molecular cancer subtyping is an important tool in predicting prognosis and developing novel precision medicine approaches. We developed a novel platform-independent gene expression-based classification system for molecular subtyping of patients with high-grade serous ovarian carcinoma (HGSOC). METHODS: Unprocessed exon array (569 tumor and nine normal) and RNA sequencing (RNA-seq; 376 tumor) HGSOC data sets, with clinical annotations, were downloaded from the Genomic Data Commons portal. Sample clustering was performed by non-negative matrix factorization by using isoform-level expression estimates. The association between the subtypes and overall survival was evaluated by Cox proportional hazards regression model after adjusting for the covariates. A novel classification system was developed for HGSOC molecular subtyping. Robustness and generalizability of the gene signatures were validated using independent microarray and RNA-seq data sets. RESULTS: Sample clustering recaptured the four known The Cancer Genome Atlas molecular subtypes but switched the subtype for 22% of the cases, which resulted in significant (P = .006) survival differences among the refined subgroups. After adjusting for covariate effects, the mesenchymal subgroup was found to be at an increased hazard for death compared with the immunoreactive subgroup. Both gene- and isoform-level signatures achieved more than 92% prediction accuracy when tested on independent samples profiled on the exon array platform. When the classifier was applied to RNA-seq data, the subtyping calls agreed with the predictions made from exon array data for 95% of the 279 samples profiled by both platforms. CONCLUSION: Isoform-level expression analysis successfully stratifies patients with HGSOC into groups with differing prognosis and has led to the development of robust, platform-independent gene signatures for HGSOC molecular subtyping. The association of the refined The Cancer Genome Atlas HGSOC subtypes with overall survival, independent of covariates, enhances the clinical annotation of the HGSOC cohort.
Subject(s)
Biomarkers, Tumor , Computational Biology/methods , Gene Expression Profiling , Ovarian Neoplasms/diagnosis , Ovarian Neoplasms/genetics , Algorithms , Cluster Analysis , Cystadenocarcinoma, Serous/diagnosis , Cystadenocarcinoma, Serous/etiology , Cystadenocarcinoma, Serous/mortality , Female , Gene Expression Profiling/methods , Gene Expression Regulation, Neoplastic , Humans , Kaplan-Meier Estimate , Molecular Diagnostic Techniques/methods , Molecular Diagnostic Techniques/standards , Neoplasm Grading , Ovarian Neoplasms/mortality , Prognosis , Proportional Hazards ModelsABSTRACT
PURPOSE: To investigate the place of the transcription factor nuclear kappa B (NF-kB), which is a marker of chronic inflammation, in the etiology of the ovarian carcinoma. METHODS: NFkB analysis with the immunohistochemical method has been performed. To evaluate immunohistochemical NF-kB expression in the ovarian tissue, the H-score method. H-score = ∑ Pi (i+1), where ''Pi'' is the percentage of stained cells in each intensity category (0-100%) and ''i'' is the intensity indicating weak (i=1), moderate (i=2) or strong staining (i=3). RESULTS: It has been seen that, the mean H score is statistically significantly higher in the patient group with serous and musinous adenocarcinoma diagnosis than the two other patient groups (p<0.005). CONCLUSIONS: Factor nuclear kappa B is an important mediator that acts in the chronic inflammation. The highest expression rates are determined by the immunohistochemical method in the ovarian cancer group.
Subject(s)
Cystadenocarcinoma, Serous/etiology , Cystadenocarcinoma, Serous/pathology , Cystadenoma, Serous/etiology , Cystadenoma, Serous/pathology , NF-kappa B/analysis , Ovarian Neoplasms/etiology , Ovarian Neoplasms/pathology , Adult , Aged , Aged, 80 and over , Analysis of Variance , Biomarkers, Tumor/analysis , Cystadenocarcinoma, Serous/diagnosis , Cystadenoma, Serous/diagnosis , Female , Humans , Immunohistochemistry , Middle Aged , Ovarian Neoplasms/diagnosis , Ovary/pathology , Reference Values , Statistics, NonparametricABSTRACT
Purpose: The majority of ovarian carcinomas are of high-grade serous histology, which is associated with poor prognosis. Surgery and chemotherapy are the mainstay of treatment, and molecular characterization is necessary to lead the way to targeted therapeutic options. To this end, various computational methods for gene expression-based subtyping of high-grade serous ovarian carcinoma (HGSOC) have been proposed, but their overlap and robustness remain unknown.Experimental Design: We assess three major subtype classifiers by meta-analysis of publicly available expression data, and assess statistical criteria of subtype robustness and classifier concordance. We develop a consensus classifier that represents the subtype classifications of tumors based on the consensus of multiple methods, and outputs a confidence score. Using our compendium of expression data, we examine the possibility that a subset of tumors is unclassifiable based on currently proposed subtypes.Results: HGSOC subtyping classifiers exhibit moderate pairwise concordance across our data compendium (58.9%-70.9%; P < 10-5) and are associated with overall survival in a meta-analysis across datasets (P < 10-5). Current subtypes do not meet statistical criteria for robustness to reclustering across multiple datasets (prediction strength < 0.6). A new subtype classifier is trained on concordantly classified samples to yield a consensus classification of patient tumors that correlates with patient age, survival, tumor purity, and lymphocyte infiltration.Conclusions: A new consensus ovarian subtype classifier represents the consensus of methods and demonstrates the importance of classification approaches for cancer that do not require all tumors to be assigned to a distinct subtype. Clin Cancer Res; 24(20); 5037-47. ©2018 AACR.
Subject(s)
Biomarkers, Tumor , Cystadenocarcinoma, Serous/diagnosis , Cystadenocarcinoma, Serous/etiology , Ovarian Neoplasms/diagnosis , Ovarian Neoplasms/etiology , Algorithms , Clinical Decision-Making , Consensus , Cystadenocarcinoma, Serous/mortality , Disease Management , Disease Susceptibility , Female , Gene Expression Profiling , Humans , Neoplasm Grading , Ovarian Neoplasms/mortality , Prognosis , ROC Curve , Reproducibility of ResultsABSTRACT
High-grade serous epithelial ovarian cancer (HGSOC) is the fifth leading cause of cancer death in women and the first among gynecological malignancies. Despite an initial response to standard chemotherapy, most HGSOC patients relapse. To improve treatment options, we must continue investigating tumor biology. Tumor characteristics (e.g., risk factors and epidemiology) are valuable clues to accomplish this task. The two most frequent risk factors for HGSOC are the lifetime number of ovulations, which is associated with increased oxidative stress in the pelvic area caused by ovulation fluid, and a positive family history due to genetic factors. In the attempt to identify novel genetic factors (i.e., genes) associated with HGSOC, we observed that several genes in linkage with HGSOC are expressed in the ciliated cells of the fallopian tube. This finding made us hypothesize that ciliated cells, despite not being the cell of origin for HGSOC, may take part in HGSOC tumor initiation. Specifically, malfunction of the ciliary beat impairs the laminar fluid flow above the fallopian tube epithelia, thus likely reducing the clearance of oxidative stress caused by follicular fluid. Herein, we review the up-to-date findings dealing with HGSOC predisposition with the hypothesis that fallopian ciliated cells take part in HGSOC onset. Finally, we review the up-to-date literature concerning genes that are located in genomic loci associated with epithelial ovarian cancer (EOC) predisposition that are expressed by the fallopian ciliated cells.
Subject(s)
Cystadenocarcinoma, Serous/etiology , Cystadenocarcinoma, Serous/metabolism , Fallopian Tubes/metabolism , Mucous Membrane/metabolism , Ovarian Neoplasms/etiology , Ovarian Neoplasms/metabolism , Animals , Biomarkers , Carcinoma, Ovarian Epithelial/diagnosis , Carcinoma, Ovarian Epithelial/etiology , Carcinoma, Ovarian Epithelial/metabolism , Cystadenocarcinoma, Serous/diagnosis , Disease Susceptibility , Fallopian Tubes/pathology , Female , Genetic Predisposition to Disease , Genetic Variation , Humans , Mucous Membrane/pathology , Neoplasm Grading , Neoplastic Stem Cells/metabolism , Oncogenes , Ovarian Neoplasms/diagnosisABSTRACT
Abstract Purpose: To investigate the place of the transcription factor nuclear kappa B (NF-kB), which is a marker of chronic inflammation, in the etiology of the ovarian carcinoma. Methods: NFkB analysis with the immunohistochemical method has been performed. To evaluate immunohistochemical NF-kB expression in the ovarian tissue, the H-score method. H-score = ∑ Pi (i+1), where ''Pi'' is the percentage of stained cells in each intensity category (0-100%) and ''i'' is the intensity indicating weak (i=1), moderate (i=2) or strong staining (i=3). Results: It has been seen that, the mean H score is statistically significantly higher in the patient group with serous and musinous adenocarcinoma diagnosis than the two other patient groups (p<0.005). Conclusions: Factor nuclear kappa B is an important mediator that acts in the chronic inflammation. The highest expression rates are determined by the immunohistochemical method in the ovarian cancer group.
Subject(s)
Humans , Female , Adult , Middle Aged , Aged , Aged, 80 and over , Ovarian Neoplasms/etiology , Ovarian Neoplasms/pathology , NF-kappa B/analysis , Cystadenoma, Serous/etiology , Cystadenoma, Serous/pathology , Cystadenocarcinoma, Serous/etiology , Cystadenocarcinoma, Serous/pathology , Ovarian Neoplasms/diagnosis , Ovary/pathology , Reference Values , Immunohistochemistry , Biomarkers, Tumor/analysis , Analysis of Variance , Cystadenoma, Serous/diagnosis , Cystadenocarcinoma, Serous/diagnosis , Statistics, NonparametricABSTRACT
BACKGROUND: Ovarian carcinoma is not a single disease, but rather a collection of subtypes with differing molecular properties and risk profiles. The most common of these, and the subject of this work, is high-grade serous ovarian carcinoma (HGSC). METHODS: In this population-based study we identified a cohort of 441,382 women resident in Western Australia who had ever been admitted to hospital in the State. Of these, 454 were diagnosed with HGSC. We used Cox regression to derive hazard ratios (HRs) comparing the risk of disease in women who had each of a range of medical diagnoses and surgical procedures with women who did not. RESULTS: We found an increased risk of HGSC associated with a diagnosis of pelvic inflammatory disease (PID) (HR 1.47, 95% CI 1.04-2.07) but not with a diagnosis of infertility or endometriosis with HRs of 1.12 (95% CI 0.73-1.71) and 0.82 (95% CI 0.55-1.22) respectively. A personal history of breast cancer was associated with a three-fold increase in the rate of HGSC. Increased parity was associated with a reduced risk of HGSC in women without a personal history of breast cancer (HR 0.57; 95% CI 0.44-0.73), but not in women with a personal history of breast cancer (HR 1.48; 95% CI 0.74-2.95). CONCLUSIONS: Our finding of an increased risk of HGSC associated with PID lends support to the hypothesis that inflammatory processes may be involved in the etiology of HGSC.
Subject(s)
Breast Neoplasms/complications , Cystadenocarcinoma, Serous/etiology , Ovarian Neoplasms/etiology , Parity , Pelvic Inflammatory Disease/complications , Cohort Studies , Cystadenocarcinoma, Serous/epidemiology , Cystadenocarcinoma, Serous/pathology , Female , Humans , Infertility/complications , Middle Aged , Neoplasm Grading , Ovarian Neoplasms/epidemiology , Ovarian Neoplasms/pathology , Pregnancy , Risk Factors , Western Australia/epidemiologyABSTRACT
Objective: To determine any association between the menopausal status and epithelial ovarian cancer coexisting with endometriosis (EOC-E). In addition, the prevalence and possible risk factors were assessed. Methods: Medical records of 172 women with epithelial ovarian cancer between January 2011 and December 2016 at Prapokklao Hospital were reviewed and divided into two groups: EOC-E defined as the case group and without endometriosis (EOC-NE) as the control group. Results: The proportion of EOC-E was 18% (31/172). There were no significant differences between the two groups in baseline clinical characteristics and presenting symptoms except for history of smoking and abnormal uterine bleeding found more often in EOC-E cases. Most EOC-E were of clear cell histological type followed by endometrioid and serous types (35.5, 25.8 and 22.6 %; respectively). The clear cell type was 8 times more likely in the EOC-E than in the EOC-NE (OR 8.0, 95% CI 2.97-21.89, p-value <0.001) group. Nulliparity and smoking increased risk of EOC-E 2 and 7 times, respectively (OR 2.3, 95%CI 1.03-5.00, p-value 0.041 and OR 7.4, 95%CI 1.18-46.63, p-value 0.032). Conclusions: EOC-E are relatively common. Abnormal uterine bleeding is the only significant presenting symptom in the EOC-E as compared with the EOC-NE group. Endometriosis was a predictive factor for clear cell and endometrioid type I EOC. Menopausal status and age were not associated with a presentation of endometriosis with EOC
Subject(s)
Adenocarcinoma, Clear Cell/etiology , Adenocarcinoma, Mucinous/etiology , Cystadenocarcinoma, Serous/etiology , Endometrial Neoplasms/etiology , Endometriosis/complications , Menopause , Ovarian Neoplasms/etiology , Adenocarcinoma, Clear Cell/pathology , Adenocarcinoma, Mucinous/pathology , Cystadenocarcinoma, Serous/pathology , Endometrial Neoplasms/pathology , Female , Follow-Up Studies , Humans , Middle Aged , Ovarian Neoplasms/pathology , Prognosis , Risk Factors , ThailandABSTRACT
Animal and experimental data suggest that anti-Müllerian hormone (AMH) serves as a marker of ovarian reserve and inhibits the growth of ovarian tumors. However, few epidemiologic studies have examined the association between AMH and ovarian cancer risk. We conducted a nested case-control study of 302 ovarian cancer cases and 336 matched controls from nine cohorts. Prediagnostic blood samples of premenopausal women were assayed for AMH using a picoAMH enzyme-linked immunosorbent assay. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated using multivariable-adjusted conditional logistic regression. AMH concentration was not associated with overall ovarian cancer risk. The multivariable-adjusted OR (95% CI), comparing the highest to the lowest quartile of AMH, was 0.99 (0.59-1.67) (Ptrend : 0.91). The association did not differ by age at blood draw or oral contraceptive use (all Pheterogeneity : ≥0.26). There also was no evidence for heterogeneity of risk for tumors defined by histologic developmental pathway, stage, and grade, and by age at diagnosis and time between blood draw and diagnosis (all Pheterogeneity : ≥0.39). In conclusion, this analysis of mostly late premenopausal women from nine cohorts does not support the hypothesized inverse association between prediagnostic circulating levels of AMH and risk of ovarian cancer.
Subject(s)
Adenocarcinoma, Clear Cell/etiology , Adenocarcinoma, Mucinous/etiology , Biomarkers/blood , Cystadenocarcinoma, Serous/etiology , Endometrial Neoplasms/etiology , Ovarian Neoplasms/etiology , Adenocarcinoma, Clear Cell/blood , Adenocarcinoma, Clear Cell/epidemiology , Adenocarcinoma, Mucinous/blood , Adenocarcinoma, Mucinous/epidemiology , Adult , Anti-Mullerian Hormone/blood , Case-Control Studies , Cohort Studies , Cystadenocarcinoma, Serous/blood , Cystadenocarcinoma, Serous/epidemiology , Endometrial Neoplasms/blood , Endometrial Neoplasms/epidemiology , Female , Follow-Up Studies , Humans , Middle Aged , Neoplasm Grading , Neoplasm Staging , Ovarian Neoplasms/blood , Ovarian Neoplasms/epidemiology , Premenopause , Prognosis , Young AdultABSTRACT
Purpose: A major challenge in platinum-based cancer therapy is the clinical management of chemoresistant tumors, which have a largely unknown pathogenesis at the level of epigenetic regulation.Experimental Design: We evaluated the potential of using global loss of 5-hydroxymethylcytosine (5-hmC) levels as a novel diagnostic and prognostic epigenetic marker to better assess platinum-based chemotherapy response and clinical outcome in high-grade serous tumors (HGSOC), the most common and deadliest subtype of ovarian cancer. Furthermore, we identified a targetable pathway to reverse these epigenetic changes, both genetically and pharmacologically.Results: This study shows that decreased 5-hmC levels are an epigenetic hallmark for malignancy and tumor progression in HGSOC. In addition, global 5-hmC loss is associated with a decreased response to platinum-based chemotherapy, shorter time to relapse, and poor overall survival in patients newly diagnosed with HGSOC. Interestingly, the rescue of 5-hmC loss restores sensitivity to platinum chemotherapy in vitro and in vivo, decreases the percentage of tumor cells with cancer stem cell markers, and increases overall survival in an aggressive animal model of platinum-resistant disease.Conclusions: Consequently, a global analysis of patient 5-hmC levels should be included in future clinical trials, which use pretreatment with epigenetic adjuvants to elevate 5-hmC levels and improve the efficacy of current chemotherapies. Identifying prognostic epigenetic markers and altering chemotherapeutic regimens to incorporate DNMTi pretreatment in tumors with low 5-hmC levels could have important clinical implications for newly diagnosed HGSOC disease. Clin Cancer Res; 24(6); 1389-401. ©2017 AACR.
Subject(s)
5-Methylcytosine/analogs & derivatives , Cellular Reprogramming/genetics , Cystadenocarcinoma, Serous/etiology , Cystadenocarcinoma, Serous/metabolism , Epigenesis, Genetic , Ovarian Neoplasms/etiology , Ovarian Neoplasms/metabolism , 5-Methylcytosine/metabolism , Animals , Cell Survival/drug effects , Combined Modality Therapy , Cystadenocarcinoma, Serous/mortality , Cystadenocarcinoma, Serous/pathology , DNA Methylation , DNA-Binding Proteins/genetics , DNA-Binding Proteins/metabolism , Dioxygenases/genetics , Dioxygenases/metabolism , Disease Models, Animal , Disease Progression , Female , Gene Expression Regulation, Neoplastic , Humans , Mice , Neoplasm Grading , Ovarian Neoplasms/mortality , Ovarian Neoplasms/pathology , Prognosis , Proto-Oncogene Proteins/genetics , Proto-Oncogene Proteins/metabolism , Recurrence , Survival Analysis , Xenograft Model Antitumor AssaysABSTRACT
OBJECTIVE: Ovarian cancer is the fifth most common cancer in women and one of the leading causes of death from gynecological malignancies. Despite of its clinical importance, ovarian tumorigenesis is poorly understood and prognosis remains poor. This is particularly true for the most common type of ovarian cancer, high-grade serous ovarian cancer. RESULTS: Two models are considered, whether it arises from the ovarian surface epithelium or from the fallopian tube. The first model is based on (1) the pro-inflammatory environment caused by ovulation events, (2) the expression pattern of ovarian inclusion cysts, and (3) biomarkers that are shared by the ovarian surface epithelium and malignant growth. The model suggesting a non-ovarian origin is based on (1) tubal precursor lesions, (2) genetic evidence of BRCA1/2 mutation carriers, and (3) recent animal studies. Neither model has clearly demonstrated superiority over the other. Therefore, one can speculate that high-grade serous ovarian cancer may arise from two different sites that undergo similar changes. Both tissues are derived from the same embryologic origin, which may explain how progenitor cells from different sites can respond similar to stimuli within the ovaries. However, distinct molecular drivers, such as BRCA deficiency, may still preferentially arise from one site of origin as precancerous mutations are frequently seen in the fallopian tube. CONCLUSIONS: Confirming the origin of ovarian cancer has important clinical implications when deciding on cancer risk-reducing prophylactic surgery. It will be important to identify key biomarker to uncover the sequence of ovarian tumorigenesis.
Subject(s)
Cystadenocarcinoma, Serous/etiology , Fallopian Tubes/pathology , Ovarian Neoplasms/etiology , Ovary/pathology , Animals , Cell Transformation, Neoplastic/metabolism , Cystadenocarcinoma, Serous/genetics , Cystadenocarcinoma, Serous/pathology , Epithelium/pathology , Fallopian Tube Neoplasms/pathology , Female , Humans , Models, Biological , Ovarian Neoplasms/genetics , Ovarian Neoplasms/pathology , Receptors, G-Protein-CoupledABSTRACT
BACKGROUND: The somatic molecular profiles of basal-like breast cancers and high-grade serous ovarian cancers share many similarities, leading to the hypothesis that they have similar aetiologies, in which case they should occur together in the same patient more often than expected. METHODS: We identified 545 women with double independent primary cancers of the breast and ovary reported to the California Cancer Registry from 1999 to 2013 and examined the coincidence of subtype combinations. RESULTS: For most subtype combinations the observed frequencies were similar to their expected frequencies, but in 103 observed cases vs 43.8 expected (O/E=2.35; 95% CI 1.90-2.81) a triple-negative breast tumour (typically basal-like) was matched with a serous ovarian tumour (typically high-grade). CONCLUSIONS: The results provide compelling evidence that basal-like breast cancer and high-grade serous ovarian cancer share a much more similar aetiology than breast and ovarian cancers more broadly. Further research is needed to clarify the influence of germ-line BRCA1 mutations and other risk factors on these results.